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Acute myeloid leukaemia (AML) is one of the most common
malignancies seen to occur in human populations exposed to
ionising radiation.
1 Mouse models have been widely used for
quantitative and mechanistic studies of radiation leukaemogen-
esis; further, there is a similarity in the histopathological changes
found in human AML and mouse AML. The majority of mouse
radiation-induced AMLs (rAMLs) carry deletions of chromosome 2,
and the Sfpi1/PU.1 haematopoietic transcription factor is located
within the commonly deleted chromosome 2 region.
2 In most
rAMLs and rAML cell lines (70%), Sfpi1/PU.1 suffers hemizygous
loss accompanied by point mutations in the region encoding the
ETS DNA-binding domain, leading to base substitutions at the
R235 residue of the protein.
2- -4 Sfpi1/PU.1 mutations have been
identiﬁed in human AML, but these are rare; in contrast, the most
common mutations in human AML involve the Flt3 receptor tyrosine
kinase. Most of these mutations are internal tandem duplication
(Flt3-ITD) of 3--400bp
5 that result in ligand-dependent dimerisation
and receptor phosphorylation. The presence of a Flt3-ITD appears
to confer a more severe phenotype and a poor prognosis for AML
sufferers. The majority of the remaining non-ITD mutations in Flt3
occur in the second tyrosine kinase domain, being mostly point
mutations within codon 835 or the deletion of 836.
6
In this study, for the ﬁrst time, we identify Flt3 mutations in a
murine model of rAML, providing a direct mechanistic link
between the mouse and human AML.
In all, 30 mouse rAML cases were screened for Flt3-ITD using
PCR, 20 on an F1 CBA/H x C57BL/Lia background and 10 on an
inbred CBA/H background. All but nine of the CBA/H and rAMLs
have been described previously,
2,4 the new AML samples were
generated from mice irradiated with 3Gy X-rays at MRC Harwell,
Oxfordshire, UK. Animals were bred and maintained in accordance
with the UK Animals (Scientiﬁc Procedures) Act 1986.
For each AML, DNA was extracted from leukaemic spleen tissue
using a MagNA pure compact instrument (Roche Diagnostics GmbH,
Mannheim, Germany). Flt3-ITD mutations were detected using PCR
with primers designed to amplify the region covering exons 14 and
15, syntenic to the region containing ITD in human FLT3 (F: 50-
GCAATTTAGGTACGAGAGTCAGC-30,R :5 0-CTTTTAGCATCTTCACCGC
CACC-30;S i g m a - A l d r i c h ,P o o l e ,U K ) .T h ep r e s e n c eo fFlt3-ITD was
indicated by an increase in amplicon size and then conﬁrmed by
sequencing. Figure 1a provides a representative example of PCR
analysis of events (Flt3-ITD) in mouse rAML. Flt3-ITDs, ranging in size
from approximately 10 to 30bp, were identiﬁed in three cases. Of
these, two AMLs were heterozygous for the mutation and one
homozygous. DNA sequencing of PCR products conﬁrmed the
presence of ITDs in these three AMLs: A, B and C of 18, 27 and 36bp
in length, respectively, at independent insertion sites (Figure 1b).
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Figure 1. (a) Representative Flt3-ITD PCR analysis of a panel of murine rAMLs run on a 2% agarose gel. The normal amplicon size is 333bp.
Presence of Flt3-ITD is indicated by an additional larger band on the gel. The gel is loaded as indicated above the image. ‘CBA’ and ‘C57’ refer
to normal spleen DNA from CBA/H and C57BL/Lia, respectively; ‘Brain’ refers to brain tissue from the animal in which AML A developed and
represents a normal tissue control; and AMLs A--F refer to independent AML samples. The genetic alterations identiﬁed in the AMLs are
summarised below each sample (Flt3-ITD: þ, presence and  , absence; del2: þ, presence and  , absence; nucleotide 703 base at nucleotide
703 of Sfpi1/PU.1. C is wild type and T is mutant (the Tallele leading to arginine 235 being converted to cysteine in Sfpi1/PU.1 protein). (b) CBA
Flt3 Exon 14 and 15 sequence illustrating the three insertion sites and sequence of Flt3 ITD in AMLs A--C. ITD lengths for each are 18, 27 and
36bp, respectively. (c) Predicted Flt3 protein sequence of AMLs A--C showing inserted amino acids.
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acids being inserted in frame (Figure 1c).
The majority of rAMLs in this study (23/30, 77%) carry
chromosome 2 deletions as identiﬁed by loss-of-heterozygosity
or in situ hybridisation methods.
2,7 Of these, most (19/23, 82%)
carry Sfpi1/PU.1 mutations affecting R235 (Table 1). However, all
Flt3-ITD occurred in rAMLs in which no Sfpi1/PU.1 involvement was
identiﬁed, either as chromosome 2 deletions or as Sfpi1/PU.1 exon
5 mutations. Out of seven rAMLs without Sfpi1/PU.1 alterations,
three have presented with Flt3-ITDs (B43%). To check for the
presence of small Flt3-ITD mutations in those AMLs that were
assessed as negative for the ITD mutations using PCR and gel-
based assays, Flt3 exon 14/15 PCR products from a sample of 11
AMLs (9 from CBA/H animals and 2 from CBA x C57BL/6Lia
animals; 8 with chromosome 2 deletions and 3 without chromo-
some 2 deletions) were sequenced. None of these was found to
have any exon 14/15 Flt3 DNA sequence alterations. Therefore, no
ITDs were found in any of these rAMLs with chromosome 2
deletions (with or without Sfpi1/PU.1 exon 5 mutations). Statistical
analysis using Fisher’s exact test to compare Flt3-ITD and
chromosome 2 deletion status indicated that the absence of
AMLs with both Flt3-ITD and chromosome 2 deletions was
statistically signiﬁcant (P¼0.0086). These ﬁndings suggest that
the involvement of Flt3-ITD and Sfpi1/PU.1 is mutually exclusive in
this model. No phenotypic differences between AMLs with the
involvement of Flt3-ITD and Sfpi1/PU.1 have been observed.
To rule out the possibility of point mutations within the second
tyrosine kinase domain of Flt3, we screened samples that showed
no Sfpi1/PU.1 involvement using PCR with primers covering exon
20 syntenic to the mutated region in human AML (F: 50-AGA
AGAGGCTGGCAGAAGAA-30,R :5 0-CCGTAGGACCAGACGTCACT-30).
Fragments were sequenced along with corresponding matched
brains (negative controls). No cases of point mutations were
identiﬁed in any of the rAMLs, indicating that Flt3-ITD is the only
Flt3 mutation present in these rAMLs.
This study has therefore identiﬁed Flt3-ITD mutations in
approximately 10% of mouse rAMLs for the ﬁrst time, but only
in cases without Sfpi1/PU.1 involvement. The Flt3-ITDs are in the
size range identiﬁed in humans
6 and although rare in our samples,
show greater parallels to human AML. The three insertions are
predicted to lead to 6--12 novel amino acids being inserted in
frame in Flt3 with two of these insertions in the tyrosine-rich
juxtamembrane domain; these ITDs are therefore similar to those
seen in human AML cases.
8 The ﬁndings also suggest that
radiation can cause Flt3-ITD mutations directly.
There are therefore two identiﬁed pathways leading to rAML
in the mouse, the most common involving loss/mutation of
Sfpi1/PU.1 and the other involving mutation of Flt3. Future work
will help establish the mechanistic relationship between the
mouse rAMLs and the human disease. The Flt3-ITD-carrying
AMLs, although rare, may be of value in the preclinical evaluation
of FLT3 inhibitors as therapeutic agents for myeloid leukaemia.
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Table 1. Summary of the frequency of Flt3-ITD mutations,
chromosome 2 deletions and Sfpi1/PU.1 R235 point mutations
in a panel of 30 radiation-induced AMLs induced on two different
genetic backgrounds
AML genetic
background
Del2 Number
of samples
Number with
Flt3-ITD (%)
Number with
Sfpi-1/PU.1 exon 5
mutation (%)
CBA/
H C57BL
+ 17 0 (0.0) 14 (82.4)
  3 2 (66.7) 0 (0.0)
CBA/H + 6 0 (0.0) 5 (83.3)
  4 1 (25) 0 (0.0)
Abbreviations: AML, acute myeloid leukaemia; Del2, chromosome 2 deletion.
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